POPULATION COUNCIL's RU 486 NDA SUBMISSION EXPECTED WITHIN 16 MONTHS
Executive Summary
POPULATION COUNCIL's RU 486 NDA SUBMISSION EXPECTED WITHIN 16 MONTHS, FDA Commissioner Kessler testified at a May 16 hearing before Rep. Wyden's (D-Ore.) House Small Business/Regulation Subcommittee. "We have been told by the Population Council that they anticipate that [an] application will take between nine and 16 months to prepare," Kessler said. In a press conference preceding the hearing, HHS Secretary Shalala announced that Roussel Uclaf is donating its U.S. patent rights to the abortifacient RU 486 (mifepristone) to the New York City-based non-profit research organization.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth